These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31189978)

  • 1. Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial.
    Morimoto T; Sakuma I; Sakuma M; Tokushige A; Natsuaki M; Asahi T; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    Sci Rep; 2019 Jun; 9(1):8537. PubMed ID: 31189978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
    Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.
    Jin SM; Park SW; Yoon KH; Min KW; Song KH; Park KS; Park JY; Park IB; Chung CH; Baik SH; Choi SH; Lee HW; Lee IK; Kim DM; Lee MK
    Diabetes Obes Metab; 2015 May; 17(5):511-5. PubMed ID: 25523633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial.
    Hirai H; Higa M; Morimoto T; Sakuma M; Arasaki O; Nomiyama T; Node K; Ueda S; Shimabukuro M
    J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31905896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
    Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
    JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
    Hayashi T; Fukui T; Nakanishi N; Yamamoto S; Tomoyasu M; Osamura A; Ohara M; Yamamoto T; Ito Y; Hirano T
    Cardiovasc Diabetol; 2017 Jan; 16(1):8. PubMed ID: 28086872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.
    Yamada Y; Terauchi Y; Watada H; Nakatsuka Y; Shiosakai K; Washio T; Taguchi T
    Adv Ther; 2018 Mar; 35(3):367-381. PubMed ID: 29488152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
    Onoue T; Goto M; Wada E; Furukawa M; Okuji T; Okada N; Kobayashi T; Iwama S; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Seino Y; Suga H; Banno R; Hamada Y; Ando M; Yamamori E; Arima H
    PLoS One; 2020; 15(1):e0228004. PubMed ID: 31990936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
    Frias JP; Zimmer Z; Lam RLH; Amorin G; Ntabadde C; Iredale C; O'Neill EA; Engel SS; Kaufman KD; Makimura H; Crutchlow MF
    Diabetes Obes Metab; 2019 May; 21(5):1128-1135. PubMed ID: 30609212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
    Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
    Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
    Tahara N; Yamagishi SI; Bekki M; Kodama N; Nakamura T; Sugiyama Y; Oshige T; Kumashiro Y; Honda A; Tahara A; Igata S; Fukumoto Y
    Curr Vasc Pharmacol; 2016; 14(6):552-562. PubMed ID: 27357182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
    Bailey RA; Vijapurkar U; Meininger G; Rupnow MF; Blonde L
    Clin Ther; 2015 May; 37(5):1045-54. PubMed ID: 25795432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
    Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
    Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.